Announcement • Mar 07
Acticor Biotech SAS(ENXTPA:ALACT) dropped from Next Biotech Index Acticor Biotech SAS has been dropped from the Next Biotech Index. Announcement • Oct 14
Acticor Biotech Announces Chief Financial Officer Changes Acticor Biotech announced the appointment of François Guillet as Chief Financial Officer, replacing Éric Cohen who is leaving to pursue other projects. With over 30 years' experience in financial management, François Guillet will bring to Acticor Biotech his expertise in financial structuring and optimization. His role will be to strengthen the management of the company's finances, while ensuring long-term visibility of Acticor Biotech's global strategy. François Guillet has held positions of great responsibility in companies in a wide variety of sectors, including the high-tech sector, from software publishing at Bea, Oracle and Adobe to the internet, electronics and e-commerce at Monnier Frères. He has contributed to restructuring and turnaround projects in mid-sized companies, with scope extended to Human Resources, Purchasing and Sales Administration. His previous assignments have included managing accounting closures, due diligence and managing multicultural teams internationally, reinforcing his versatility as a financial leader. Announcement • Oct 11
Acticor Biotech Repositions Glenzocimab in the Treatment of Myocardial Infarction ACTICOR BIOTECH provided an update on its clinical developments evaluating glenzocimab in the treatment of myocardial infarction. LIBERATE: A phase 2b study evaluating glenzocimab in the treatment of myocardial infarction. The LIBERATE phase 2b, randomized and double-blind study will include more than 212 patients suffering from ST-Elevation Myocardial Infarction (STEMI) who are scheduled to undergo percutaneous coronary intervention (PCI). The study’s primary objective is to assess the safety and efficacy of glenzocimab 1,000 mg compared to placebo, in reducing the size of the myocardial infarction 90 days post-event. This study is being conducted in partnership with the University of Birmingham (UK), with clinical experts from the Institute of Cardiovascular Sciences and University Hospitals Birmingham NHS Foundation Trust. The two leading clinical research sites, Queen Elizabeth Hospital in Birmingham and Northern General Hospitalin Sheffield, have been actively recruiting patients since January 2024. To date, 27 patients have been recruited, and study results are expected in Fourth Quarter of 2026. GLORIA: A phase 2 study evaluating glenzocimab in myocardial infarction treatment. A new phase 2 study GLORIA, randomized and double-blind, is being prepared to evaluate glenzocimab in the treatment of myocardial infarction. The study will enroll around 300 patients suffering from STEMI upon emergency admission to cardiac intensive care units. The study’s primary objective is likewise to assess the efficacy of glenzocimab for reducing the surface of myocardial infarct at Day 90 post PCI (Percutaneous Coronary Intervention), as well as safety. The study plans to test several dose levels and optimize the mode of administration to suit the time required for this emergency procedure. The aim of launching this second study, which could be promoted by the Company, is to provide all the clinical and regulatory elements required for a phase 3 registration as early as 2027, while evolving the product's mode of administration to facilitate the next stage of development and, later, adoption by clinicians. Patient recruitment could begin in First Quarter 2025, subject to the Company's financing or the continuation of the project as envisaged in the receivership procedure. 
